Phathom Retained Earnings from 2010 to 2025

PHAT Stock

USD 7.90 0.07 0.89%

Phathom Pharmaceuticals Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Phathom Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2018-09-30

Previous Quarter

-1.3 B

Current Value

-1.4 B

Quarterly Volatility

390.5 M

Covid

Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 15.9 M, Depreciation And Amortization of 635.5 K or Interest Expense of 75.6 M, as well as many indicators such as Price To Sales Ratio of 8.82, Dividend Yield of 0.0 or Days Sales Outstanding of 243. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Phathom Stock

Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Latest Phathom Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Phathom Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Phathom Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.26 B)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Phathom Retained Earnings Regression Statistics

	Arithmetic Mean	(331,344,841)
	Geometric Mean	19,718,433
	Coefficient Of Variation	(138.61)
	Mean Deviation	380,679,676
	Median	(1,288,000)
	Standard Deviation	459,271,158
	Sample Variance	210930T
	Range	1.3B
	R-Value	(0.88)
	Mean Square Error	52363.6T
	R-Squared	0.77
	Slope	(84,555,235)
	Total Sum of Squares	3163949.9T

Phathom Retained Earnings History

	2025	-1.2 B
	2024	-1.3 B
	2023	-928.7 M
	2022	-727.1 M
	2021	-529.4 M
	2020	-385.5 M
	2019	-256.4 M

Other Fundumenentals of Phathom Pharmaceuticals

Retained Earnings Total Equity

Phathom Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Long Term Debt	Long Term Debt Total	Common Stock	Property Plant Equipment	Net Receivables
Total Assets		-0.19	0.09	0.88	-0.88	-0.87	0.85	0.93	0.8	0.39	0.92	1.0	0.99	-0.04	0.8	0.76	0.86	0.75	0.51
Total Stockholder Equity	-0.19		0.88	-0.35	-0.25	0.6	-0.19	-0.12	-0.73	0.82	-0.03	-0.17	-0.12	0.49	-0.66	-0.47	-0.62	-0.42	-0.76
Net Tangible Assets	0.09	0.88		-0.1	-0.46	0.3	0.0	0.13	-0.44	0.89	0.21	0.11	0.15	0.48	-0.43	-0.34	-0.36	-0.26	-0.36
Current Deferred Revenue	0.88	-0.35	-0.1		-0.67	-0.92	0.9	0.93	0.83	0.22	0.88	0.88	0.85	0.02	0.84	0.88	0.83	0.73	0.57
Net Debt	-0.88	-0.25	-0.46	-0.67		0.57	-0.75	-0.8	-0.46	-0.72	-0.83	-0.89	-0.92	-0.2	-0.44	-0.46	-0.54	-0.56	-0.15
Retained Earnings	-0.87	0.6	0.3	-0.92	0.57		-0.78	-0.85	-0.97	0.03	-0.8	-0.87	-0.84	0.26	-0.94	-0.86	-0.93	-0.76	-0.78
Accounts Payable	0.85	-0.19	0.0	0.9	-0.75	-0.78		0.85	0.69	0.31	0.81	0.85	0.81	0.35	0.7	0.73	0.76	0.86	0.39
Capital Surpluse	0.93	-0.12	0.13	0.93	-0.8	-0.85	0.85		0.71	0.45	0.99	0.94	0.93	-0.02	0.78	0.85	0.77	0.7	0.43
Total Liab	0.8	-0.73	-0.44	0.83	-0.46	-0.97	0.69	0.71		-0.21	0.64	0.79	0.75	-0.31	0.91	0.76	0.93	0.74	0.85
Net Invested Capital	0.39	0.82	0.89	0.22	-0.72	0.03	0.31	0.45	-0.21		0.52	0.4	0.45	0.41	-0.15	0.03	-0.1	-0.02	-0.38
Short Long Term Debt	0.92	-0.03	0.21	0.88	-0.83	-0.8	0.81	0.99	0.64	0.52		0.93	0.92	-0.02	0.74	0.81	0.73	0.67	0.36
Total Current Assets	1.0	-0.17	0.11	0.88	-0.89	-0.87	0.85	0.94	0.79	0.4	0.93		0.99	-0.03	0.79	0.76	0.85	0.75	0.51
Net Working Capital	0.99	-0.12	0.15	0.85	-0.92	-0.84	0.81	0.93	0.75	0.45	0.92	0.99		-0.06	0.75	0.73	0.8	0.7	0.46
Short Term Debt	-0.04	0.49	0.48	0.02	-0.2	0.26	0.35	-0.02	-0.31	0.41	-0.02	-0.03	-0.06		-0.33	-0.26	-0.2	0.17	-0.31
Long Term Debt	0.8	-0.66	-0.43	0.84	-0.44	-0.94	0.7	0.78	0.91	-0.15	0.74	0.79	0.75	-0.33		0.92	0.97	0.75	0.71
Long Term Debt Total	0.76	-0.47	-0.34	0.88	-0.46	-0.86	0.73	0.85	0.76	0.03	0.81	0.76	0.73	-0.26	0.92		0.85	0.67	0.46
Common Stock	0.86	-0.62	-0.36	0.83	-0.54	-0.93	0.76	0.77	0.93	-0.1	0.73	0.85	0.8	-0.2	0.97	0.85		0.8	0.72
Property Plant Equipment	0.75	-0.42	-0.26	0.73	-0.56	-0.76	0.86	0.7	0.74	-0.02	0.67	0.75	0.7	0.17	0.75	0.67	0.8		0.48
Net Receivables	0.51	-0.76	-0.36	0.57	-0.15	-0.78	0.39	0.43	0.85	-0.38	0.36	0.51	0.46	-0.31	0.71	0.46	0.72	0.48

Click cells to compare fundamentals

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-1.3 B	-1.2 B
Retained Earnings Total Equity	-476.4 M	-500.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC